Roth Capital Expects Aduro Biotech 'To Shine' Next Year After Meeting Management

Loading...
Loading...
  • Shares of Aduro BioTech Inc ADRO have appreciated 46.14 percent over the past three months, to reach $33.63 on December 16.
  • Roth Capital’s Joseph Pantginis has reiterated a Buy rating on the company, with a price target of $68.
  • While adding the stock to the ROTH Focus List, Pantaginis mentioned the company’s robust cash balance and potential pipeline expansion could help it “shine” in 2016.

According to the Roth Capital report, “With two major partners in hand, a strong cash balance to fund the future of development and potential pipeline expansion we look to Aduro solidifying its place as an immunotherapy leader.”

Analyst Joseph Pantginis mentioned that Aduro Bio Tech’s “multi-pronged approach” was likely to support opportunities for business development going forward.

Apart from the strong IPO in April 2015, Pantginis believes that the company has made meaningful progress during the year, including “including 1) CRS-207 data for mesothelioma and 2) both Janssen partnered products, ADU-714 and ADU-214 are now in the clinic, both of which were generated from Aduro's LADD platform.”

However, the stock experienced volatility due to the increased weakness in the healthcare sector, as well as “a misguided attempt to drive shares down because of a trial protocol violation needing to be labeled listeriosis,” the report said.

On the other hand, the company has been making strategic moves to become a commercial entity, intending to maintain the U.S. rights for its products, along with potential partnering across its pipeline outside the U.S. as well.

Loading...
Loading...
Posted In: Analyst ColorLong IdeasReiterationAnalyst RatingsTrading IdeasJoseph PantginisROTH Capital Partners
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...